The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Research collaboration covers multiple antibody research programs
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Subscribe To Our Newsletter & Stay Updated
